Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases

Clin Cancer Res. 2022 Aug 2;28(15):3179-3181. doi: 10.1158/1078-0432.CCR-22-1137.

Abstract

The activity of KRAS inhibitors against brain metastases is relatively unexplored. The recent work on preclinical models and preliminary data from the ongoing KRYSTAL-1 phase Ib clinical trial support the potential of adagrasib (MRTX849) to penetrate the central nervous system and provide control of KRASG12C brain metastases. See related article by Sabari et al., p. 3318.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Acetonitriles
  • Brain Neoplasms* / genetics
  • Brain Neoplasms* / secondary
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Humans
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Piperazines
  • Pyrimidines

Substances

  • Acetonitriles
  • Piperazines
  • Pyrimidines
  • adagrasib